Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S293
- Development stage
- Preclinical
- Lead developer
- University of Colorado
- Modality
- Peptides
01
Overview
S293 is a peptide mimetic of the C-terminal regulatory site of connexin-36 (Cx36) designed to competitively inhibit cytokine-mediated Cx36 phosphorylation. In diabetes, pro-inflammatory cytokines and free fatty acids disrupt Cx36 gap junction coupling in pancreatic beta-cells, leading to a loss of synchronized calcium dynamics and impaired insulin secretion. By preventing Cx36 phosphorylation, S293 rescues gap junction permeability, restores coordinated calcium oscillations, and protects beta-cells from cytokine-induced apoptosis.
- Other names
- Cx36 S293 peptideCx-36 S293 peptideCx 36 S293 peptideS293 mimetic peptideS-293 mimetic peptideS 293 mimetic peptideS293 peptideS-293 peptideS 293 peptide
02
Targets
PRKCD (Protein kinase C delta)PKA (Cyclic amp-dependent protein kinase)
Beyond the preview
Go deeper on S293.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S293.